Straight Path Wealth Management Lineage Cell Therapeutics, Inc. Transaction History
Straight Path Wealth Management
- $208 Million
- Q3 2024
A detailed history of Straight Path Wealth Management transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Straight Path Wealth Management holds 16,200 shares of LCTX stock, worth $9,072. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,200
Previous 16,200
-0.0%
Holding current value
$9,072
Previous $16,000
12.5%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
120Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$23.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$5.35 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$4.82 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$2.8 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$2.8 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $95.1M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...